17a-hydroxy-4-androstene-3-one and derivatives thereof

Details 17a-hydroxy-4-androstene-3-one and derivatives thereof 17a-hydroxy-4-androstene-3-one and derivatives thereof

2000-11-10

2002-08-13

Badio, Barbara P. (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

55

Reexamination Certificate

active

06432939

ABSTRACT:

This invention relates to 17&agr;-hydroxy-4-androstene-3-one and its derivatives, methods for their production, and pharmaceuticals containing these compounds.
It is known from the state of the art that natural testosterone and follicle-stimulating hormone (FSH) are important regulatory components of spermatogenesis. As the gametes themselves have no FSH receptors, hormonal signals have to be transferred via Sertoli cells that produce unknown signals required for spermatogenesis (de Kretser D. M. et al., Hum. Reprod., 1998, 13, pp. 1-8). The FSH concentration is regulated using inhibin-B (negative feedback) that is released from the Sertoli cells. Inhibin-B itself inhibits the secretion of FSH, thereby suppressing spermatogenesis. This is why inhibin-B is considered to be a marker of spermatogenesis (Pierik F. H. et al., J. Clin. Endocrinol. Metab., 1998, 83, pp. 3110-3114) and why it plays a vital role in the paracrine and endocrine regulation of spermatogenesis as a function of its concentration. A correlation of inhibin-B and sperm concentration has also been reported (Klingmuller D. et al., Hum. Reprod., 1997, 12, pp. 3276-3278; Jensen D. K. et al., J. Clin. Endocrinol. Metab., 1997, 82, pp. 4059-4063).
Epitestosterone, an androgene that is secreted in the testicles, has long been regarded as an inactive epimer of testosterone. It has been found in the past few years, however, that it has either an inhibiting or an increasing effect on FSH levels in the plasma depending on its dose (Bicikova M. et al., J. Steroid. Biochem. Mol. Biol., 1993, 45, pp. 321-324). In this context, epitestosterone is described as a competitive inhibitor of androgen receptors (antiandrogen) (Lapcik O. et al., J. Endocrinol., 1994, 143, pp. 353-358; Starka L. et al., Vnitr. Lek., 1996, 42, pp. 620-623). In addition, it has been described that epitestosterone inhibits epididymal and prostatic 5&agr;-reductase (Monsalve A. and Blaquier J. A., Steroids, 1977, 30, p. 41-51; Starka L. et al., J. Steroid. Biochem., 1989, 33, pp. 1019-1021). Starka et al. discussed an assumed connection between antiandrogenic activity and 5&agr;-reductase inhibition (Starka L. et al., J. Steroid. Biochem., 1989, 33, pp. 1019-1021). Furthermore, it influences the conversion of testosterone into estrogens by aromatization (Broulik P. D. et al., Bone, 1997, 20, pp. 473-475).
It is one of the problems of this invention to provide known and new compounds with high efficacy for contraceptive uses and for hormone replacement therapy in men.
This problem is solved according to the invention by providing 17&agr;-hydroxy-4-androstene-3-one or its derivatives of the general formula I
wherein
the residues R each independently represent a hydrogen atom or an OR
2
residue, where
the R
2
residues independently represent hydrogen atoms, saturated or unsaturated, straight-chain or branched alkyl or acyl groups containing 1 to 6 C atoms,
R
1
is a saturated or unsaturated, straight-chain or branched acyl group containing 1 to 18 C atoms, a benzoyl, methylbenzoyl, or alkylbenzoyl group containing up to 10 C atoms, a sulfite or a glucuronyl residue, and each R′ residue represents a hydrogen atom or form a double bond together with the single bond between C
11
and C
12
, and their pharmaceutically tolerable salts.
It is preferred according to the invention that R
1
is an undecanoyl, lauroyl, tridecanoyl, myristoyl, pentadecanoyl, palmitoyl, acetyl, caproyl, benzoyl, valeroyl, sulfite, or glucuronyl residue.
The compounds according to the invention of the general formula I can be administered either in their free form or as pharmacologically effective salts. Suitable examples of these salts of compounds of the general formula I include addition salts of common physiologically compatible inorganic and organic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, malic acid, citric acid, salicylic acid, adipinic acid, and benzoic acid. Other acids that can be used are described, for example, in Arzneimittelforschung, vol. 10, pp. 224-225, Birkhäuser Verlag, Basel and Stuttgart, 1966, and in Journal of Pharmaceutical Sciences, vol. 66, pp. 1-5 (1977).
The addition salts of acids are obtained in a generally known way by intermixing the free base or its solutions with the respective acid or its solutions in an organic solvent such as methanol, ethanol, n-propanol, or isopropanol, or a lower ketone such as acetone, methyl ethyl ketone, or methyl isobutyl ketone, or an ether such as diethyl ether, tetrahydrofurane, or dioxane. Mixtures of the solvents mentioned above can be used to improve crystallization. In addition, physiologically compatible aqueous solutions of acid addition salts of the compound of the general formula I can be produced in an aqueous acidic solution.
The acid addition salts of compounds of the general formula I can be converted into the free base in a generally known way, e. g. using alkalies or ion exchangers. Other salts can be obtained by reacting the free base with inorganic or organic acids, especially such acids that are suited for forming therapeutically applicable salts. These and other salts of the new compound such as picrate can also be used to purify the free base by converting it into a salt, isolating this salt, and releasing the base from it.
The new derivatives of the invention of 17&agr;-hydroxy-4-androstene-3-one are produced by partial synthesis (see Tetrahedron Lett. 35, p. 2329 (1994)). To do this, 14,15-unsaturated 17&agr;-hydroxy-4-androstene-3-one is reacted with methyl dihalides and a zinc-copper pair or diazomethane and zinc iodide to the respective 14&agr;, 15&agr;-methylene-17&agr;-ols. The derivatives of the invention that contain a 14,15-methylene group are synthesized with knowledge of the chemical reactions described in German patent no. DE 42 39 946. Alternatively, you the following method can be applied: To maintain an existing 17-oxo grouping, transform the derivative into ethylene ketal. The following steps are adding bromine to produce the respective 16&agr; bromine compound and transformation into the &Dgr;
15
compound in a hydrobromination step. After isomerization to produce the &Dgr;
14
compound and splitting up said compound, the existing 17-oxosteroids are reduced with complex metal hydrides or diborane in a tetrahydrofurane solution at −10 to +10° C. Various substituents can be inserted, for example, at positions 11 or 12, again by partial synthesis. A suitable oxygen function is inserted in the molecule by adding ceric ammonium nitrate (see Terahedron Lett. 35, p. 8599 (1994)).
Another object of this invention are pharmaceutical preparations for oral, parenteral, topical, rectal, subcutaneous, intravenous, intramuscular, intraperitoneal, intranasal, intrabuccal or sublingual application which, in addition to the common substrates and diluents, contain as active ingredient at least one compound according to the invention of the general formula I or its acid addition salt.
The pharmaceuticals of the invention are produced in a generally known way using the common solid or liquid substrates or diluents and the commonly used adjuvants of pharmaceutical engineering, their dosage depending on the intended application. Preferred preparations are forms of application suitable for oral administration. Such forms of application include tablets, film tablets, lozenges, capsules, pills, powder, solutions or suspensions, or depot systems.
Parenteral preparations such as injection solutions can also be taken into consideration, of course. Another example of suitable preparations are suppositories.
The respective tablets can be produced, for example, by intermixing the active ingredient with known adjuvants, e. g. inert diluents such as dextrose, sugar, sorbitol, mannite, polyvinylpyrrolidone, blasting agents such as corn starch or alginic acid, binding agents such as starch or gelatin, lubricants such as magnesium stearate or talc and/or agents for producing a depot effect such

Affiliated with

Also associated with

Rating

17a-hydroxy-4-androstene-3-one and derivatives thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 17a-hydroxy-4-androstene-3-one and derivatives thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 17a-hydroxy-4-androstene-3-one and derivatives thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2948364